Day: December 6, 2020

Aptose Presents Highlights from ASH and Corporate Update Event

SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology (ASH) Annual Meeting. The Aptose management team reviewed the current clinical status of CG-806, Aptose’s oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor currently in two Phase 1 a/b trials, one trial in patients with relapsed or refractory acute myeloid leukemia (AML), and the other trial in patients with relapsed or refractory B cell malignancies; and the team also reviewed the clinical status of APTO-253, a first-in-class small molecule MYC inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic...

Continue reading

Duck Creek Technologies Partners with Ebix Australia to Offer Insurers a Proven, Secure eCommerce Processing Solution

Sydney, Dec. 06, 2020 (GLOBE NEWSWIRE) — Duck Creek Technologies (NASDAQ: DCT) announced today that it has partnered with Ebix Australia, provider of Sunrise Exchange, a leading B2B eCommerce service that enables insurers and intermediaries to transact securely in real time over a broad and expanding range of insurance products and services. Sunrise Exchange allows insurance professionals to process quotes, submit and respond to new business, make enquiries, endorse and renew policies, and complete cancellations and lapses across most classes of general insurance products. Duck Creek has built an adapter for the Ebix Sunrise Exchange and has made it available to all its customers through its Content Exchange as part of its partnership with Ebix Australia.“The rate of change in the insurance eCommerce sector has increased exponentially...

Continue reading

BIC: Disclosure Of Trading In Own Shares For November 2020

Disclosure Of Trading In Own SharesFor November 2020CLICHY – December 03, 2020In compliance with general regulation on share buy-backs, SOCIÉTÉ BIC declares below the transactions made on its own shares for November 2020 :–       No transactions for November 2020.ABOUT BICBIC is a world leader in stationery, lighters and shavers. For more than 75 years, the Company has honored the tradition of providing high-quality, affordable products to consumers everywhere. Through this unwavering dedication, BIC has become one of the most recognized brands and is a trademark registered worldwide. Today, BIC products are sold in more than 160 countries around the world and feature iconic brands such as Cello®, Conté®, BIC FlexTM, Lucky Stationery, Made For YOUTM, Soleil®, Tipp-Ex®, Wite-Out® and more. In 2019, BIC Net Sales were 1,949.4 million...

Continue reading

BIC : Déclaration Des Transactions Sur Actions Propres De Novembre 2020

               Déclaration Des Transactions Sur Actions PropresDe Novembre 2020CLICHY, – 03 Décembre, 2020Conformément à la réglementation relative aux rachats d’actions, SOCIÉTÉ BIC déclare au mois de novembre 2020 les transactions suivantes réalisées sur ses propres actions :–       Pas de transaction en novembre 2020.À PROPOS DE BICBIC est un des leaders mondiaux des articles de papeterie, des briquets et des rasoirs. Depuis plus de 75 ans, l’entreprise fabrique des produits de grande qualité accessibles à tous, partout dans le monde. Cette vocation a permis au Groupe de faire de sa marque, enregistrée dans le monde entier, l’une des plus reconnues. Aujourd’hui, les produits BIC® sont vendus dans plus de 160 pays et possèdent des marques emblématiques telles que Cello®, Conté®, BIC Flex™, Lucky Stationery, Made For YOU™, Soleil®,...

Continue reading

BIC: Disclosure of total number of voting rights and number of shares forming the capital as of November 30, 2020

Disclosure of total number of voting rights and number of shares forming the capitalas of November 30, 2020CLICHY – December 03, 2020Article L 233-8-II of the French “Code de Commerce” and Article 223-16 of the General Regulations of the French “Autorité des Marchés Financiers”.As of November 30, 2020, the total number of issued shares of SOCIÉTÉ BIC is 45,532,240 shares, representing:66,966,176 voting rights,66,419,073 voting rights excluding shares without voting rightsABOUT BICBIC is a world leader in stationery, lighters and shavers. For more than 75 years, the Company has honored the tradition of providing high-quality, affordable products to consumers everywhere. Through this unwavering dedication, BIC has become one of the most recognized brands and is a trademark registered worldwide. Today, BIC products are sold in more than...

Continue reading

BIC : Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital au 30 novembre 2020

                               Déclaration du nombre total de droits de vote et du nombre d’actions composant le capitalau 30 novembre 2020CLICHY, – 03 Décembre, 2020Article L 233-8-II du code de Commerce et article 223-16 du Règlement général de l’Autorité des Marchés Financiers.Au 30 novembre 2020, le capital social de SOCIÉTÉ BIC est composé de 45 532 240 actions, représentant :66 966 176 droits de vote,66 419 073 droits de vote nets des actions privées de droits de voteÀ PROPOS DE BICBIC est un des leaders mondiaux des articles de papeterie, des briquets et des rasoirs. Depuis plus de 75 ans, l’entreprise fabrique des produits de grande qualité accessibles à tous, partout dans le monde. Cette vocation a permis au Groupe de faire de sa marque, enregistrée dans le monde entier, l’une des plus reconnues. Aujourd’hui, les produits BIC®...

Continue reading

MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patientsMedian duration of response = 8.13 monthsROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a single-arm, registrational study of flotetuzumab, an investigational, bispecific CD123 × CD3 DART® molecule, in patients with primary induction failure (PIF) and early relapsed (less than six months, or ER6) acute myeloid leukemia (AML). The data were presented at the 62nd Annual Meeting of the American Society of Hematology (ASH) taking place December 5-8, 2020.In the open label study of flotetuzumab, 44 AML patients had disease classified...

Continue reading

Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology

Results Demonstrate Ability of AlloCAR T™ Therapy to Selectively Kill CD70 Expressing Leukemic CellsCoupled with Previous Findings in Renal Cell Carcinoma (RCC), Results Highlight the Potential of ALLO-316 to Treat Both Hematologic Malignancies and Solid TumorsInvestigational New Drug (IND) Application for ALLO-316 Cleared by U.S. Food and Drug Administration (FDA); Phase 1 Trial in RCC to Start in 2021SOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical findings of ALLO-316, an AlloCAR T™ therapy targeting CD70, in models of acute myeloid leukemia (AML). Data were presented in a poster session today at the 62nd Annual Meeting of...

Continue reading

Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting

SEATTLE, Dec. 06, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new real-world data highlighting the clinical utility of Adaptive’s next-generation sequencing (NGS) clonoSEQ® Assay to assess minimal residual disease (MRD) in patients with multiple myeloma. The data are being presented at the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition, held virtually December 5-8. Additional study results demonstrating the impact of Adaptive’s clonoSEQ Assay in chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and mantle cell lymphoma (MCL) are also being presented at the meeting in 45 other abstracts.MRD...

Continue reading

BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement

—Data presented at the 62nd American Society of Hematology Annual Meeting—RESEARCH TRIANGLE PARK, N.C., Dec. 06, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor under development as monotherapy for paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases, showed complete in vitro blockade of both hemolysis of PNH erythrocytes and accumulation of C3 fragments on PNH erythrocytes, indicating that BCX9930 monotherapy has the potential to inhibit both intravascular and extravascular hemolysis.In the study, BCX9930 was highly specific for the alternative pathway and, after oral dosing of BCX9930 in primates, alternative pathway activity was completely suppressed.The data were presented at the 62nd American Society...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.